Novartis gene therapy for fatal disease delivers strong sales

Novartis gene therapy for fatal disease delivers strong sales

STAT Plus: Novartis gene therapy for fatal childhood disease delivers strong sales during fourth quarter

By ADAM FEUERSTEIN

RUBY WALLAU FOR STAT

Zolgensma, the Novartis gene therapy for infants and the world’s most expensive medicine, continues to perform well commercially.

READ MORE